1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The incidence and impact of clostridioides difficile infection (CDI) on outcomes after allogeneic hematopoietic cell transplant (alloHCT) - a CIBMTR study
    Meeting Abstract

    Ramanathan, M.; Savani, B. B.; He, N. Y.; Kim, S.; Chen, M.; Chemaly, R.; Dandoy, C. E.; Perales, M. A.; Riches, M. L.; Ustun, C.
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis
    Meeting Abstract

    Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quality of life in patients <=70 years of age with chronic lymphocytic leukemia treated frontline with ibrutinibrituximab versus fludarabine cyclophosphamide rituximab: Analysis from ECOG-ACRIN E1912
    Meeting Abstract

    Pophali, P. A.; Wang, X. V.; Zhao, F.; Kay, N. E.; Hanson, C. A.; Thomas, M. L.; O'Brien, S. M.; Barrientos, J.; Paietta, E. M.; Leis, J. F.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies
    Meeting Abstract

    Patel, M. R.; Monga, V.; Jauhari, S.; Stevens, D.; Masarova, L.; McKean, M.; Mauro, D.; Viscusi, J.; Scherle, P.; Bhagwat, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the beat AML master trial
    Meeting Abstract

    Patel, P.; Ruppert, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Predictors of central nervous system (CNS) involvement in North American adult T-cell leukemia lymphoma (ATLL) and their survival pattern
    Meeting Abstract

    Patel, R.; Rahman, S.; Shah, N.; Thakkar, A.; Acuna-Villaorduna, A.; Shah, U. A.; Herrera, D. A.; De Castro, A.; Mustafa, J.; Khatun, F.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of allogeneic hematopoietic cell transplantation (HCT) as consolidation following CD19 chimeric antigen receptor (CAR) T cell therapy for treatment of relapsed acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Park, J. H.; Nikiforow, S.; Kim, S.; Hu, Z. H.; Moskop, A.; Ahmed, S.; Abid, M. B.; Badar, T.; Bredeson, C.; Brown, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save